Moderna Begins Ebola Vaccine Trial as FDA Decision on Flu Shot Looms

What's Happening? Moderna has initiated a Phase 1 clinical trial for its experimental Ebola vaccine targeting the Bundibugyo strain. The trial, conducted in Canada, will assess the vaccine's safety and immune response in 80 adults. This development comes as the U.S. FDA is set to decide on Moderna's

Science Uncovered

SEE ALL

Rapid Read

Brazil Identifies Fish-Killing Pathogens, Urges Enhanced Aquaculture Surveillance

Rapid Read

USDA Tests Genetically Engineered Insect to Combat Screwworm Outbreak in Livestock

Rapid Read

Wild Deer Contribute Millions of Tonnes of Methane Annually, Study Finds

What is the story about?

What's Happening?

Moderna has initiated a Phase 1 clinical trial for its experimental Ebola vaccine targeting the Bundibugyo strain. The trial, conducted in Canada, will assess the vaccine's safety and immune response in 80 adults. This development comes as the U.S. FDA

is set to decide on Moderna's seasonal influenza vaccine for adults aged 50 and older. The Ebola vaccine trial is supported by the Coalition for Epidemic Preparedness Innovations, which has committed up to $50 million for early development.

Why It's Important?

The trial represents a significant step in addressing the Bundibugyo strain of Ebola, for which no approved vaccine currently exists. This effort could enhance global health security and expand Moderna's infectious disease portfolio. The upcoming FDA decision on the flu vaccine is also critical, as it could impact Moderna's market position and influence public health strategies for influenza prevention.